P53 IMMUNOSTAINING DISTINGUISHES MALIGNANT FROM BENIGN LESIONS OF THE GALLBLADDER

被引:59
作者
OOHASHI, Y
WATANABE, H
AJIOKA, Y
HATAKEYAMA, K
机构
[1] NIIGATA UNIV,SCH MED,DEPT PATHOL 1,NIIGATA 951,JAPAN
[2] NIIGATA UNIV,SCH MED,DEPT SURG 1,NIIGATA,JAPAN
关键词
CYTOLOGIC ATYPIA; GALLBLADDER CARCINOMA; KI-67; P53-IMMUNOSTAINING; PT STAGE;
D O I
10.1111/j.1440-1827.1995.tb03380.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The expression of p53 protein was studied in formalin-fixed paraffin-embedded specimens of 41 well-differentiated adenocarcinomas of the gall-bladder, six cases of acute cholecystitis and 23 cases of chronic cholecystitis, using a monoclonal p53 (PAb 1801) antibody and streptavidin-biotin. p53 staining was divided into diffuse, focal or sporadic patterns. The relationship between the p53 Labeling Index (p53 LI) and cellular proliferation was also investigated using monoclonal Ki-67 (MIB1) antibody. Twenty-four of the 41 carcinomas (58.5%) had a diffuse staining pattern with a high p53 LI (47-93%) and 9.8% (4/41) had a focal staining pattern with an intermediate p53 LI (22-34%), with no relation to pT stage, tumor size, histologic type or grade of cytologic atypia, The p53 LI was higher than the Ki-67 LI in these tumors except for one. On the other hand, p53 staining was completely sporadic in the non-neoplastic specimens with a low p53 LI (0.2-2.8%). The p53-positive cells in these specimens were located only within areas of Ki-67-positive cells. In conclusion, p53-protein overexpression occurs as an early event in approximately 70% of well-differentiated adenocarcinomas of the gall-bladder, and this alteration is maintained during progression from intramucosal to invasive carcinoma. p53 immunostaining can distinguish malignant from benign lesions of the gall-bladder.
引用
收藏
页码:58 / 65
页数:8
相关论文
共 24 条
  • [1] CARCINOMA INSITU OF THE GALLBLADDER - A CLINICOPATHOLOGIC STUDY OF 18 CASES
    ALBORESSAAVEDRA, J
    ANGELESANGELES, A
    MANRIQUE, JD
    HENSON, DE
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1984, 8 (05) : 323 - 333
  • [2] ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION
    BANKS, L
    MATLASHEWSKI, G
    CRAWFORD, L
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03): : 529 - 534
  • [3] BEAHRS OH, 1992, MANUAL STAGING CANCE
  • [4] CAMPO E, 1991, CANCER RES, V51, P4436
  • [5] P53 EXPRESSION IN BREAST-CANCER
    CATTORETTI, G
    RILKE, F
    ANDREOLA, S
    DAMATO, L
    DELIA, D
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (02) : 178 - 183
  • [6] MONOCLONAL-ANTIBODIES AGAINST RECOMBINANT PARTS OF THE KI-67 ANTIGEN (MIB-1 AND MIB-3) DETECT PROLIFERATING CELLS IN MICROWAVE-PROCESSED FORMALIN-FIXED PARAFFIN SECTIONS
    CATTORETTI, G
    BECKER, MHG
    KEY, G
    DUCHROW, M
    SCHLUTER, C
    GALLE, J
    GERDES, J
    [J]. JOURNAL OF PATHOLOGY, 1992, 168 (04) : 357 - 363
  • [7] DAVIDOFF AM, 1991, CANCER RES, V51, P2605
  • [8] ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM
    GANNON, JV
    GREAVES, R
    IGGO, R
    LANE, DP
    [J]. EMBO JOURNAL, 1990, 9 (05) : 1595 - 1602
  • [9] P53 IMMUNOSTAINING AS A MARKER OF MALIGNANT DISEASE IN DIAGNOSTIC CYTOPATHOLOGY
    HALL, PA
    RAY, A
    LEMOINE, NR
    MIDGLEY, CA
    KRAUSZ, T
    LANE, DP
    [J]. LANCET, 1991, 338 (8765) : 513 - 513
  • [10] INCREASED EXPRESSION OF MUTANT FORMS OF P53 ONCOGENE IN PRIMARY LUNG-CANCER
    IGGO, R
    GATTER, K
    BARTEK, J
    LANE, D
    HARRIS, AL
    [J]. LANCET, 1990, 335 (8691) : 675 - 679